Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Proof of Principle Program - Phase I

McMaster University

$159,000.00

Evaluation of a Novel Chlamydia Vaccine Based on Type III Secretion Proteins

FY 2013-14

Summary
Chlamydia trachomatis is the number one sexually acquired bacterial infection worldwide accounting for over 5 million new cases every year in North America. Sexually acquired infections with Chlamydia trachomatis affect both genders and over 50% of infections do not cause symptoms meaning that individuals may be infected but not know it. Undetected or undiagnosed infections in women can lead to infections of the upper genital tract (fallopian tubes) resulting in infertility. Antibiotics can be used successfully to treat Chlamydial infection but we do not yet have a vaccine to prevent infection. We have identified three proteins from Chlamydia pneumoniae that when injected into mice elicit antibody production that blocks infection by Chlamydia trachomatis. In this study we will evaluate the ability of the homologous proteins from Chlamydia trachomatis to make antibody in mice and protect the mice from infection with Chlamydia trachomatis. If successful these proteins will be used to develop a chlamydial vaccine.
Program
Proof of Principle Program - Phase I
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
308072
Name
Mahony James B
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Proof of Principle
Projecttitle
Evaluation of a Novel Chlamydia Vaccine Based on Type III Secretion Proteins
Programtype2
Operating Grants
Orgnameinp2
McMaster University
Cihramount2
$159,000
Cihrequipment2
$0
Programname2
Proof of Principle Program - Phase I
Keyworddelim
Chlamydia; Vaccine
Abstract
Chlamydia trachomatis is the number one sexually acquired bacterial infection worldwide accounting for over 5 million new cases every year in North America. Sexually acquired infections with Chlamydia trachomatis affect both genders and over 50% of infections do not cause symptoms meaning that individuals may be infected but not know it. Undetected or undiagnosed infections in women can lead to infections of the upper genital tract (fallopian tubes) resulting in infertility. Antibiotics can be used successfully to treat Chlamydial infection but we do not yet have a vaccine to prevent infection. We have identified three proteins from Chlamydia pneumoniae that when injected into mice elicit antibody production that blocks infection by Chlamydia trachomatis. In this study we will evaluate the ability of the homologous proteins from Chlamydia trachomatis to make antibody in mice and protect the mice from infection with Chlamydia trachomatis. If successful these proteins will be used to develop a chlamydial vaccine.
Competitiondate
201402
Approvedterm2
1 yr 0 mth
Pinamesdelim
Mahony, James B
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $159,000~ $0~
McMaster University - $159,000 Grant (2013-14) | Canada Spends